Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Aug 17;17(3):1470320316657450.
doi: 10.1177/1470320316657450. Print 2016 Jul.

Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis

Affiliations
Meta-Analysis

Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis

Xiyue Li et al. J Renin Angiotensin Aldosterone Syst. .

Abstract

Objective: The accuracy of aldosterone/direct renin concentration ratio (ADRR) as a screening test in patients with primary aldosteronism (PA) varies widely across the studies. Therefore, we conducted a meta-analysis to assess the accuracy of ADRR.

Methods: A literature search was performed in PubMed, Embase, and the Cochrane library published between April 1971-February 2016. Studies focusing on the accuracy of ADRR for PA screening were included. Two authors independently extracted information regarding patient characteristics, antihypertensives status, true positives, true negatives, false positives, and false negatives. The random-effects model was used for statistical analysis. Heterogeneity was explored by subgroup analysis and meta-regression.

Results: Nine studies involving 974 patients were included. The overall sensitivity, specificity, area under the curve, and diagnostic odds ratio of ADRR were 0.89 (95% confidence interval (CI) 0.84-0.93), 0.96 (95% CI 0.95-0.98), 0.985 and 324 respectively, with substantial heterogeneity. Meta-regression showed that antihypertensive status affects the ADRR and may account for the heterogeneity (p=0.03). Subgroup analysis of patients who discontinued the antihypertensives revealed a sensitivity of 0.99 (95% CI, 0.95-1.00) and a specificity of 0.98 (95% CI, 0.96-0.99).

Conclusions: This study demonstrates the efficacy of ADRR as a screening test for PA. However, as antihypertensive drugs can interfere with the interpretation of ADRR, it is recommended to interrupt therapy or at least replace with analogues that do not significantly affect the ADRR value.

Keywords: Primary aldosteronism; aldosterone-to-renin ratio; aldosterone/direct renin concentration; direct renin concentration; screening test.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Literature search results for identification, exclusion and selection of studies. DRC: direct renin concentration; PA: primary aldosteronism.
Figure 2.
Figure 2.
Sensitivity and specificity of studies: (a) forest plot of sensitivities and specificities of nine studies; (b) summary receiving operation characteristic curve (SROC) curve for individual studies on the accuracy of diagram primary aldosteronism (PA). AUC: area under the curve; CI: confidence interval; SE: standard error.
Figure 3.
Figure 3.
Funnel plots of publication bias in nine included studies. ESS: effective sample size.
Figure 4.
Figure 4.
(a) Forest plot of sensitivities and specificities of the five studies with discontinuation of antihypertensives. (b) Forest plot of sensitivities and specificities of the four studies without discontinuation of antihypertensives. (c) Forest plot of sensitivities and specificities of the six studies that set essential hypertension (EH) patients as control group. CI: confidence interval.

Similar articles

Cited by

References

    1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3–17. - PubMed
    1. Kaplan NM. Primary aldosteronism: An update on screening, diagnosis and treatment. J Hypertens 2008; 26: 1708–1709. - PubMed
    1. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–1248. - PubMed
    1. Gruson D, Maisin D, Lison P, et al. Two-site automated chemiluminescent assay for measurement of immunoreactive renin. Biomarkers 2011; 16: 605–609. - PubMed
    1. Morganti A and European study group for the validation of DiaSorin LDRA. A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. J Hypertens 2010; 28: 1307–1312. - PubMed

Publication types

LinkOut - more resources